Amneal Pharmaceuticals, Inc Class A Common Stock

Amneal Pharmaceuticals, Inc Class A Common Stock

Yahoo Finance • 11 days ago

Amneal (AMRX) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Thursday, July 30, 2026 at 8:30 a.m. ET CALL PARTICIPANTS Head of Investor Relations - Anthony DiMeoCo-Founder and Co-Chief Executive Officer - Chirag PatelCo-Founder and Co-Chief Executive Officer -... Full story

Yahoo Finance • 12 days ago

Amneal projects 2026 revenue of $3.1B-$3.2B while raising capex to about $150M

Earnings Call Insights: Amneal Pharmaceuticals (AMRX) Q2 2026 MANAGEMENT VIEW * "Amneal is in the midst of the most transformative period in our company's history," said (Co-Founder, Co-CEO, President & Director Chirag Patel), adding t... Full story

Yahoo Finance • 25 days ago

Amneal Expands Iohexol Injection Portfolio with U.S. FDA Approval of Additional Strengths and Presentations

Approval of iohexol injection 350 mg iodine/mL in 50 mL, 75 mL and 100 mL vials, and 300 mg iodine/mL in 50 mL vial, significantly expands Amneal’s injectable contrast portfolioPortfolio now positioned to address the majority of U.S. iohex... Full story

Yahoo Finance • 27 days ago

3 Reasons AMRX is Risky and 1 Stock to Buy Instead

3 Reasons AMRX is Risky and 1 Stock to Buy Instead Amneal currently trades at $16.70 and has been a dream stock for shareholders. It's returned 283% since July 2021, blowing past the S&P 500's 72.3% gain. The company has also beaten the i... Full story

Yahoo Finance • last month

Eli Lilly, Regeneron named to FDA pilot program to boost US drug manufacturing

[machine that makes capsules in a pharmaceutical laboratory - 3D rendering] Thibault Renard/iStock via Getty Images * Eli Lilly (LLY [https://seekingalpha.com/symbol/LLY]) and Regeneron Pharmaceuticals (REGN [https://seekingalpha.com/sy... Full story

Yahoo Finance • 2 months ago

How The Amneal Pharmaceuticals (AMRX) Story Is Shifting With Biosimilars And 2026 Expectations

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Amneal Pharmaceuticals is back in focus after analysts lifted their price target to US$16.00, alon... Full story

Yahoo Finance • 2 months ago

Amneal Announces Full Study Population Interim Phase 4 ELEVATE-PD Results, Reinforcing Previously Reported Benefits of CREXONT® in Parkinson's Disease

Amneal Pharmaceuticals LLC Phase 4 ELEVATE-PD interim data from the entire study population (n=214) continue to show clinically meaningful, consistent benefits of CREXONT across all prior treatment groups Substantial increases in daily “G... Full story

Yahoo Finance • 2 months ago

Q4 Earnings Highlights: Amneal (NASDAQ:AMRX) Vs The Rest Of The Generic Pharmaceuticals Stocks

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Amneal (NASDAQ:AMRX) and the best and worst performers in the generic pharmaceutic... Full story

Yahoo Finance • 3 months ago

2 Reasons AMRX is Risky and 1 Stock to Buy Instead

Amneal trades at $12.64 and has moved in lockstep with the market. Its shares have returned 6.2% over the last six months while the S&P 500 has gained 7.9%. Is there a buying opportunity in Amneal, or does it present a risk to your portfo... Full story

Yahoo Finance • 3 months ago

Amneal Pharmaceuticals beats top-line and bottom-line estimates; reaffirms FY26 outlook

* Amneal Pharmaceuticals press release [https://seekingalpha.com/pr/20506663-amneal-reports-first-quarter-2026-financial-results] (AMRX [https://seekingalpha.com/symbol/AMRX]): Q1 Non-GAAP EPS of $0.27 beats by $0.10. * Revenue of $722... Full story

Yahoo Finance • 3 months ago

Amneal Pharmaceuticals Kashiv Deal Puts Biosimilar Growth And Valuation In Focus

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Amneal Pharmaceuticals (NasdaqGS:AMRX) has entered a definitive agreement to acquire Kashiv BioSci... Full story

Yahoo Finance • 3 months ago

UBS Initiates Coverage of Amneal Pharmaceuticals (AMRX) With a Bullish Outlook

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) is one of the best drug stocks to buy according to analysts. On April 17, UBS initiated coverage of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) with a Buy rating and set a $19 price target. The fir... Full story

Yahoo Finance • 4 months ago

Amneal Pharmaceuticals to Buy Kashiv BioSciences, Touts Strong Preliminary Q1 Results and Biosimilar Push

Amneal Pharmaceuticals logo Key Points Amneal will acquire Kashiv BioSciences for $750 million upfront (split 50/50 cash and equity, ~8% dilution) plus up to $350 million in milestones and royalties, expecting to close in a few months an... Full story

Yahoo Finance • 4 months ago

Amneal anticipates deleveraging below 3x by 2028 as it outlines $4.3B-$4.5B 2030 revenue target following Kashiv deal

Earnings Call Insights: Amneal Pharmaceuticals (AMRX) Q1 2026 MANAGEMENT VIEW * "Today is a defining moment for Amneal." (Co-Founder, Co-CEO, President & Director Chirag Patel) "This morning, we announced that Amneal agrees to acquire... Full story

Yahoo Finance • 4 months ago

Stocks Supported by Iran Ceasefire Extension and Strong Earnings

The S&P 500 Index ($SPX) (SPY) today is up +0.84%, the Dow Jones Industrial Average ($DOWI) (DIA) is up +0.76%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +1.28%.  June E-mini S&P futures (ESM26) are up +0.80%, and June E-mini Nasdaq fut... Full story

Yahoo Finance • 4 months ago

Amneal To Acquire Kashiv BioSciences; Q1 Earnings Improve; Lifts 2026 Earnings Outlook; Stock Up

(RTTNews) - Amneal Pharmaceuticals, Inc. (AMRX), a generic medicine and biosimilar manufacturer, announced that it has entered into a definitive agreement to acquire Kashiv BioSciences in a transaction that includes $375 million of cash an... Full story

Yahoo Finance • 4 months ago

Amneal Agrees to Acquire Kashiv BioSciences to Create Global Biosimilar Leader; Reports Strong Preliminary First Quarter 2026 Financial Results and Raises FY2026 Standalone Guidance

– Acquisition Positions Amneal to Capitalize on $300B+ Global Biologics LOE Opportunity – – Transaction Accelerates Growth Profile and Diversification – – Preliminary Q1 Results Reflect Continued Growth and Raising 2026 Full Year Guidanc... Full story

Yahoo Finance • 4 months ago

Amneal Announces Positive Interim Phase 4 Data For Parkinson's Drug CREXONT

(RTTNews) - Amneal Pharmaceuticals Inc. (AMRX), a biopharmaceutical company, announced on Monday positive interim data from the Phase 4 ELEVATE-PD trial for CREXONT in treating Parkinson's disease at the 2026 American Academy of Neurology... Full story

Yahoo Finance • 4 months ago

Amneal rated Buy in new research coverage at UBS as growth pipeline expands

[Anatomical 3D illustration of the transparent human head interior.] AntonioGuillem/iStock via Getty Images UBS on Friday initiated coverage of Amneal Pharmaceuticals (AMRX [https://seekingalpha.com/symbol/AMRX]) with a Buy rating and a $... Full story

Yahoo Finance • 4 months ago

2 Cash-Producing Stocks to Research Further and 1 We Brush Off

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Not all companies are created equal, and StockStory is here to surface the ones with... Full story